Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells

Figure 1

Comparison of established cell lines and patient-derived cells. (A) MCF-10A, MCF-7, MDA-MB-231, T47D, hTERT-HMEC, PE1007070, PE1008032 and PE904557a cells were stained with 7-AAD and a lineage cocktail in combination with CD44/CD24 or (B) CD49f/EPCAM and were analyzed by FACS. The heterogeneity factor (HF) (to the right of each graph) was calculated by multiplying the percent CV of each axis. (C) MCF-10A, MCF-7, MDA-MB-231, T47D, hTERT-HMEC, PE1007070, PE1008032 and PE904557a cells were treated with 10 μM BrdU or EdU for either 30 minutes or six hours and then BrdU/EdU incorporation was analyzed by flow cytometry. The graph shows the percent BrdU/EdU positive cells. (D) Dose response curves of doxorubicin, taxol and gemcitabine against MCF-7, MDA-MB-231, T47D, PE1007070, PE1008032 and PE904557a cells after four days of treatment. Cell viability was measured using a luciferase-based ATP assay and was normalized to the vehicle control. Error bars represent standard deviation. 7-AAD, 7-amino-actinomycin D; BrdU, 5-bromo-2-deoxyuridine; CV, coefficient of variance; EdU, 5-ethynyl-2'-deoxyuridine; FACS, fluorescence activated cell sorting; human mammary epithelial cells; hTERT, human telomerase; PE, pleural effusion.

Back to article page